{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:35:29Z","timestamp":1769114129171,"version":"3.49.0"},"reference-count":27,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Psoriatic arthritis (PsA) is a chronic inflammatory disease that reduces the quality of life. This study assessed the effects of risankizumab (RZB) on the achievement of minimal clinically important differences (MCID) in patient\u2010reported outcomes (PROs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>KEEPsAKE\u20101 and \u20102 are randomized, placebo\u2010controlled Phase 3 clinical studies assessing RZB (150\u2009mg) vs. placebo (PBO) in adult patients with PsA with inadequate response or intolerance to disease\u2010modifying antirheumatic drugs and\/or biologics. Patients were randomized 1:1 to receive RZB or PBO for 24\u2009weeks; starting at Week 24, all patients received RZB 150\u2009mg through Week 52. PROs assessed were Patient's Global Assessment of Disease Activity (PtGA), Patient's Assessment of Pain, Health Assessment Questionnaire\u2014Disability Index (HAQ\u2010DI), Short\u2010Form 36 Physical and Mental Component Summary scores (PCS and MCS, respectively), 5\u2010Level EQ\u20105D (EQ\u20105D\u20105L), Functional Assessment of Chronic Illness Therapy\u2014Fatigue (FACIT\u2010Fatigue), and Work Productivity and Activity Impairment (WPAI). The proportion of patients achieving MCID at Weeks 24 and 52 are reported. Odds ratios of achieving MCID with RZB treatment at Week 24, relative to PBO, were estimated by logistic regression controlling for baseline and stratification factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In KEEPsAKE\u20101, RZB\u2010 vs. PBO\u2010treated patients were more likely to report MCID in all PROs at Week 24; similar results were obtained in KEEPsAKE\u20102, except for SF\u201036 MCS and WPAI presenteeism domain. In KEEPsAKE\u20101 and KEEPsAKE\u20102, 65% and 62% of RZB\u2010treated patients, respectively, reported MCID in PtGA at Week 24, which increased to 74% and 68%, respectively, at Week 52. Approximately 48% of all PBO\u2010treated patients reported MCID in PtGA at Week 24 and, after initiating RZB, &gt;65% reported MCID at Week 52. Results were similar in the remaining PROs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These data demonstrate that patients with PsA receiving RZB treatment are more likely to report clinically important improvements in PROs compared with patients receiving PBO.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.18475","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T14:28:40Z","timestamp":1659536920000},"page":"2120-2129","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The effect of risankizumab on achieving minimal clinically important differences in patient\u2010reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2"],"prefix":"10.1111","volume":"36","author":[{"given":"L.E.","family":"Kristensen","sequence":"first","affiliation":[{"name":"The Parker Institute Copenhagen University Hospital, Bispebjerg and Frederiksberg  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Soliman","sequence":"additional","affiliation":[{"name":"AbbVie, Inc.  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"K.","family":"Papp","sequence":"additional","affiliation":[{"name":"Probity Medical Research and K Papp Clinical Research  Waterloo ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Barcomb","sequence":"additional","affiliation":[{"name":"AbbVie, Inc.  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Eldred","sequence":"additional","affiliation":[{"name":"AbbVie, Inc.  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"\u00d6st\u00f6r","sequence":"additional","affiliation":[{"name":"Cabrini Hospital Monash University &amp; Emeritus Research  Melbourne VIC. Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.662047"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2021.101670"},{"key":"e_1_2_8_5_1","first-page":"680","article-title":"The burden of psoriatic arthritis: a literature review from a global health systems perspective","volume":"35","author":"Lee S","year":"2010","journal-title":"Pharm Ther"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200387"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-25"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1468252"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2021.02.022"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S1458"},{"key":"e_1_2_8_11_1","first-page":"200","article-title":"OP0307 Efficacy and safety of risankizumab, a selective il\u201023p19 inhibitor, in patients with active psoriatic arthritis over 24\u2009weeks: results from a phase 2 trial","volume":"77","author":"Mease P","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221019"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.2695"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.2695"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.2196\/13029"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22401"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110392"},{"issue":"10","key":"e_1_2_8_18_1","first-page":"Abstract 2268","article-title":"Patient\u2010reported outcome measures for rheumatoid arthritis: minimal important differences review","volume":"65","author":"Kitchen H","year":"2013","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110546"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2004.08.034"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-0155-5"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05893-3"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209055"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23000"},{"key":"e_1_2_8_25_1","first-page":"566","article-title":"Ixekizumab improves patient\u2010reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT\u2010P2 results to 52\u2009weeks","volume":"37","author":"Kavanaugh A","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000808"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00379-9"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00377-x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18475","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.18475","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T19:03:03Z","timestamp":1692558183000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.18475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1111\/jdv.18475"],"URL":"https:\/\/doi.org\/10.1111\/jdv.18475","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]},"assertion":[{"value":"2021-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}